Session Chair Profile

M.D., VP, Molecular, Pathology and Genomics, Syapse

Dr. Anna Berry i works in partnership with Syapse’s functional leaders to support product and service development, serves as a subject matter expert to Syapse’s customers, participates in joint-authored research and publications, and advances Syapse’s thought leadership efforts in the area of real-world evidence. Prior to her recent move to Syapse, she served for 6 years as the Deputy Director for Molecular Pathology and Genomics, and as the Scientific Director for the Personalized Medicine Program at the Swedish Cancer Institute in Seattle, and concurrently served as Director of Genomics Programs at CellNetix Pathology and Laboratories. Dr. Berry has focused professionally on genomics education and personalized medicine. In these roles, she has given numerous presentations, nationally and internationally, and has served on multiple task forces and committees for several professional organizations and coalitions, spanning Pathology and Oncology focused efforts.

 Session Abstract – PMWC 2022 Silicon Valley

Track 3, June 28

Real-world examples of two health systems actively using real-world evidence (RWE) to advance their Precision Oncology programs. Examples will be centered around clinical quality and patient care value in the areas of molecular tumor board (MTB) support, clinical trial optimization, and health disparities in BRCA testing.